1. Home
  2. EPRT vs ERAS Comparison

EPRT vs ERAS Comparison

Compare EPRT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Essential Properties Realty Trust Inc.

EPRT

Essential Properties Realty Trust Inc.

HOLD

Current Price

$30.70

Market Cap

6.6B

Sector

Real Estate

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$12.79

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPRT
ERAS
Founded
2016
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.5B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
EPRT
ERAS
Price
$30.70
$12.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
12
Target Price
$36.79
$14.25
AVG Volume (30 Days)
1.2M
4.6M
Earning Date
04-22-2026
05-08-2026
Dividend Yield
3.98%
N/A
EPS Growth
11.30
36.23
EPS
0.28
N/A
Revenue
$561,219,000.00
N/A
Revenue This Year
$17.12
N/A
Revenue Next Year
$16.27
N/A
P/E Ratio
$110.82
N/A
Revenue Growth
24.82
N/A
52 Week Low
$28.95
$1.24
52 Week High
$34.73
$24.28

Technical Indicators

Market Signals
Indicator
EPRT
ERAS
Relative Strength Index (RSI) 40.66 52.64
Support Level $29.24 $1.76
Resistance Level $31.92 $16.14
Average True Range (ATR) 0.45 0.72
MACD 0.02 0.45
Stochastic Oscillator 41.06 91.13

Price Performance

Historical Comparison
EPRT
ERAS

About EPRT Essential Properties Realty Trust Inc.

Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: